Last reviewed · How we verify

JECEVAX

National Institute of Hygiene and Epidemiology, Vietnam · Phase 3 active Biologic

JECEVAX is a live attenuated Japanese encephalitis vaccine that stimulates immune responses against Japanese encephalitis virus.

JECEVAX is a live attenuated Japanese encephalitis vaccine that stimulates immune responses against Japanese encephalitis virus. Used for Prevention of Japanese encephalitis in endemic regions.

At a glance

Generic nameJECEVAX
SponsorNational Institute of Hygiene and Epidemiology, Vietnam
Drug classLive attenuated vaccine
TargetJapanese encephalitis virus envelope proteins
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

JECEVAX contains a weakened form of Japanese encephalitis virus that triggers both humoral and cellular immune responses without causing disease. The vaccine primes the immune system to recognize and neutralize the virus upon natural exposure, providing protection against Japanese encephalitis infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: